Ovid Therapeutics Statistics
Want to see OVID full AI Analyst Report?
Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics
Total Valuation
Ovid Therapeutics has a market cap or net worth of $479.38M. The enterprise value is $381.28M.
- Market Cap
- $479.38M
- Enterprise Value
- $381.28M
Share Statistics
Ovid Therapeutics has 188,731,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 188,731,920
- Owned by Insiders
- 6.96%
- Owned by Institutions
- 44.14%
Financial Efficiency
Ovid Therapeutics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -29.46%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -29.46%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 315.30K
- Profits Per Employee
- -757.13K
- Employee Count
- 23
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ovid Therapeutics is -6.20. Ovid Therapeutics’s PEG ratio is 0.21.
- PE Ratio
- -6.20
- PS Ratio
- 330.38
- PB Ratio
- 2.60
- Price to FCF
- -8.30
- Price to Operating Cash Flow
- -8.93
- PEG Ratio
- 0.21
Income Statement
In the last 12 months, Ovid Therapeutics had revenue of 7.25M and earned -17.41M in profits. Earnings per share was -0.24.
- Revenue
- 7.25M
- Gross Profit
- 6.95M
- Operating Income
- -42.44M
- Pretax Income
- -17.41M
- Net Income
- -17.41M
- EBITDA
- -17.14M
- Earnings Per Share (EPS)
- -0.24
Cash Flow
In the last 12 months, operating cash flow was -57.78M and capital expenditures 0, giving a free cash flow of -57.78M billion.
- Operating Cash Flow
- -57.78M
- Free Cash Flow
- -57.78M
- Free Cash Flow per Share
- -0.28
Dividends & Yields
Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -12.05%
- Earnings Yield
- -8.36%
Stock Price Statistics
- Beta
- 1.80
- 52-Week Price Change
- 111.67%
- 50-Day Moving Average
- 2.51
- 200-Day Moving Average
- 2.42
- Relative Strength Index (RSI)
- 50.17
- Average Volume (3m)
- 1.93M
Important Dates
Ovid Therapeutics upcoming earnings date is Mar 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Ovid Therapeutics as a current ratio of 10.91, with Debt / Equity ratio of 10.27%
- Current Ratio
- 10.91
- Quick Ratio
- 10.91
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Ovid Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Ovid Therapeutics EV to EBITDA ratio is -10.87, with an EV/FCF ratio of -8.27.
- EV to Sales
- 329.37
- EV to EBITDA
- -10.87
- EV to Free Cash Flow
- -8.27
- EV to Operating Cash Flow
- -8.27
Balance Sheet
Ovid Therapeutics has $136.60M in cash and marketable securities with $12.35M in debt, giving a net cash position of $124.25M billion.
- Cash & Marketable Securities
- $136.60M
- Total Debt
- $12.35M
- Net Cash
- $124.25M
- Net Cash Per Share
- $0.66
- Tangible Book Value Per Share
- $0.98
Margins
Gross margin is 100.00%, with operating margin of -4700.28%, and net profit margin of -2971.33%.
- Gross Margin
- 100.00%
- Operating Margin
- -4700.28%
- Pretax Margin
- -2971.33%
- Net Profit Margin
- -2971.33%
- EBITDA Margin
- -3029.22%
- EBIT Margin
- -3057.27%
Analyst Forecast
The average price target for Ovid Therapeutics is $5.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $5.64
- Price Target Upside
- 122.16% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- -78.05%
- EPS Growth Forecast
- 63.85%
Scores
- Smart Score
- 9
- AI Score
- 52

